News

Agrospheres Announces Major Commercial Development Agreement with FMC Corporation

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and crop health, today announced the signing of a major collaboration with FMC Corporation (NYSE:FMC), a global leader in agriculture sciences. The long-term alliance represents a major milestone in launching AgroSpheres’ vertically integrated product pipeline. Powered by a recent $25M Series B funding round and construction of a new manufacturing facility, the Virginia startup is well-positioned to transition its portfolio of proprietary active ingredients to end-to-end commercial production.

The agreement will bolster FMC’s capabilities in Lepidoptera control and AgroSpheres’ speed to market for its RNA portfolio. Throughout the collaboration, AgroSpheres’ internally generated RNA targets will be used to deliver a wide range of highly potent and selective biomodalities.

“In a global market desperately in need of effective tools to combat resistance, FMC has shown foresight by investing in next-generation technologies and setting aggressive goals to meet demand for high-performance biologicals,” said Ameer Shakeel, Founder and CTO of AgroSpheres. “As leaders in bringing molecules to market, they are an ideal partner for AgroSpheres as we progress to comprehensive product development. We are excited to codevelop with the FMC team.”

“AgroSpheres’ scalable manufacturing and delivery technology got our attention, but once we took a closer look at their suite of proprietary actives, we saw significant value in a partnership,” said Dr. Seva Rostovtsev, Executive Vice President and Chief Technology Officer of FMC Corporation. “Integrating this technology into our world class insecticide portfolio will help diversify and complement our crop protection offerings.”

The technology and biomodality platform

RNA interference biomolecules have demonstrated great promise in the lab but have struggled to yield consistent results for commercial biological development. AgroSpheres’ patented AgriCell manufacturing technology offers the missing link with a highly scalable and cost-effective platform. AgriCell production of encapsulated biomolecules delivers enhanced stability, performance and targeted uptake in pests. AgroSpheres’ groundbreaking biomodality approach targets specific, yet diverse biological actions, efficiently multiplying product offerings and innovation.

“FMC is committed to finding sustainable and pollinator-friendly solutions for global insect control,” said Lisa Hoffman, PhD, Director of Development Biology and External Partnerships at FMC Corporation. “After an extensive review of RNA technologies, it was clear that AgroSpheres has the right capabilities to help us be successful in this space.”

Reese Blackwell, Chief Business Officer at AgroSpheres, underscored the company’s firm commitment to the rapid development of commercial biomodalities, aiming to provide growers with solutions that are both effective and environmentally friendly. He emphasized the need for next-generation products to address the challenges currently faced by biologicals to ensure broad farmer adoption.

“Like FMC, we aim to be at the forefront of biological input innovation,” said Blackwell. “Our development prioritizes efficacy, scalability and rapid market entry. Observing FMC’s impressive revenue generation from newly launched products over the past five years confirms that they are the perfect collaborator to expedite our pioneering technologies from the laboratory to the farm gate.”

Recent News

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients

08/14/2026

Transforming the finance function in life sciences: Empower scalable growth

Life sciences companies operate in one of the most complex business environments. Long R&D timelines, limited early-stage revenue, and dependence on external funding create a financial landscape where every decision carries strategic weight. In this context, finance is not a back-office function. It is an operational engine that drives whether a company survives, scales, or